At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This ...

If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron Pharmaceuticals Inc. ‘s Eylea blockbuster eye-disease biologic.

Eylea customers more to use a credit card; (2) these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) as a result, Regeneron offered a price ...

Regeneron paid credit card fees to distributors on the condition that those distributors did not charge purchasers of its Eylea drug more to use a credit card. The Company's payments subsidized the ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD).

clang-uml is an automatic C++ to UML class, sequence, package and include diagram generator, driven by YAML configuration files. The main idea behind the project is to easily maintain up-to-date ...

Approval for Eylea for diabetic retinopathy was based on six-month and one-year trial results from PANORAMA, a phase 3 trial that enrolled 402 patients comparing the drug with placebo.

Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting ...